Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 8,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Older Adults, Physical Function, Cognitive Function
Interventions: Curcumin, microcrystalline cellulose; Drug
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Myelodysplastic Syndromes
Interventions: ARRY-614, p38/Tie2 inhibitor; oral; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Tampa, Florida • Atlanta, Georgia • Houston, Texas

Conditions: Vaccination Refusal, Covid19, Heart Diseases
Interventions: Online Social Network and Collective Intelligence Intervention, Independent Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 4,476 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: At Risk for AD-dementia, With Subjective Cognitive Decline
Interventions: HbAEx, HbExergame; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 65 Years to 99 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Suicidal, Suicide, Attempted, Suicidal Ideation
Interventions: Electronic Safety Plan (ESP), Text support; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Birth Defects, Miscarriages, Cancer
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 1,803 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Carcinoma
Interventions: Nicotine Replacement; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Transfusional Iron Overload
Interventions: ICL670; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Oakland, California • Orange, California • Boston, Massachusetts + 4 more

Conditions: Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions: Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM; Genetic · Other
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer, High-risk Prostate Cancer
Interventions: Darolutamide, Pembrolizumab, Lupron; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myeloid, Acute
Interventions: BI 836858; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Tobacco Use Disorder, Lung Cancer
Interventions: Non-intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years to 74 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Persistent Pregnancy of Unknown Location, Ectopic Pregnancy
Interventions: Methotrexate, Uterine Evacuation, Expectant Management; Drug · Procedure · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Greenville, South Carolina

Conditions: Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia, Bone Marrow Failure Syndrome, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis of Indeterminate Potential, Hematologic Neoplasms, Hematopoietic and Lymphatic System Neoplasm, Hereditary Neoplastic Syndrome, Idiopathic Cytopenia of Undetermined Significance, Idiopathic Dysplasia of Uncertain Significance, Low Risk Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy, Buccal Swab, Clinical Evaluation, Genetic Counseling, Quality-of-Life Assessment, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Loncastuximab Tesirine, Prednisone, Rituximab, Vincristine; Drug · Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • San Diego, California

Conditions: Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
Interventions: Genetic Testing; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Genetic Polymorphisms
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Sexual Dysfunction, Sexuality and Reproductive Issues
Interventions: radiation therapy; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postoperative Nausea and Vomiting, Sex Hormone, Transgender
Interventions: Orchiectomy, Hysterectomy, Augmentation mammoplasty; Procedure
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7,348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions: Chromium; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Infertility, Pregnancy Loss, Spontaneous Abortion
Interventions: Blood Collection; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid Abuse, Prescription Drug Abuse (Not Dependent)
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,464 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Cincinnati, Ohio • Salt Lake City, Utah

Search by objective public record fields.

Curcumin and Function in Older Adults

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks

Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults (The Exergames Telerehabilitation Study)

Improving Coping to Reduce Suicide Risk Following ED Discharge

Pesticides--Health Fertility and Reproductive Risk

Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

EVOC - EVs in Obesity and Cardiometabolic Disease

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1

RCT for Women With a Persisting Pregnancy of Unknown Location

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot

NIEHS/UNC Environmental Polymorphism Study

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer

Exogenous Sex Hormones and PONV

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer

Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool